WO2026124440 - CRYSTAL FORM OF FUTIBATINIB, AND PREPARATION METHOD THEREFOR AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/124440
Publication Date
18.06.2026
International Application No.
PCT/CN2025/140994
International Filing Date
09.12.2025
Title **
[English]
CRYSTAL FORM OF FUTIBATINIB, AND PREPARATION METHOD THEREFOR AND USE THEREOF
[French]
FORME CRISTALLINE DE FUTIBATINIB, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
[Chinese]
福巴替尼晶型及其制备方法和用途
Applicants **
QILU PHARMACEUTICAL CO., LTD.
Inventors
DING, Zhaofeng
ZHANG, Ze
FU, Qiang
GAO, Yonghong
FAN, Chuanwen
Priority Data
202411813033.8
10.12.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2148 | |
| EPO | Filing, Examination, Granting | 17206 | |
| Japan | Filing, Examination, Granting | 2471 | |
| South Korea | Filing, Examination, Granting | 2777 | |
| USA | Filing, Examination, Granting | 8740 |
Total:
33,342
Contact Us
Abstract[English]
The present disclosure provides a new crystal form of futibatinib, and a preparation method therefor and a use thereof. The crystal form provided by the present disclosure has good stability, low hygroscopicity and higher solubility, and has potential advantages in improving the dissolution of a formulation, and drug efficacy or safety.[French]
La présente divulgation concerne une nouvelle forme cristalline de futibatinib, son procédé de préparation et son utilisation. La forme cristalline selon la présente divulgation présente une bonne stabilité, une faible hygroscopicité et une solubilité plus élevée, et présente des avantages potentiels pour améliorer la dissolution d'une formulation, et l'efficacité ou la sécurité du médicament.[Chinese]
本公开提供了福巴替尼的新晶型、其制备方法和用途。本公开提供的晶型稳定性好，引湿性低，溶解度更高，对提高制剂溶出、药物药效或安全性方面具有潜在优势。